[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
Farm Hosp
; 48(4): T171-T175, 2024.
Article
en En, Es
| MEDLINE
| ID: mdl-38806363
ABSTRACT
OBJETIVES The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation. METHODS:
We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus (HIV) patients over 18â¯years treated with DTG/3TC or BIC/FTC/TAF in our center were included. Persistence after first year was compared using the χ2 test. Kaplan-Meier survival analysis was performed.RESULTS:
Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (p=.001). Persistence with DGT/3TC was 1237â¯days (IC95% 1216-1258) and persistence with BIC/FTC/TAF was 986â¯days [(IC95% 950-1021); p<.001]. The difference was remained after adjusting for covariates with the cox regression model [HR=8.2 (IC95% 1.03-64.9), p=.047]. The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability.CONCLUSION:
In our study, patients have a high persistence. Patients on DTG/3TC treatment are more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF is tolerability/toxicity.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oxazinas
/
Piperazinas
/
Piridonas
/
Infecciones por VIH
/
Lamivudine
/
Fármacos Anti-VIH
/
Tenofovir
/
Emtricitabina
/
Compuestos Heterocíclicos con 3 Anillos
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
/
Es
Revista:
Farm Hosp
Asunto de la revista:
FARMACIA
/
HOSPITAIS
Año:
2024
Tipo del documento:
Article
Pais de publicación:
España